Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 4/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17381643 | 0.83 | CHRNB2 (0.36) | GSK3AGSK3BPDGFRBKDRFFAR1 | |
| SCHEMBL2120457 | 0.82 | PDGFRB (0.43) | GSK3AGSK3BPDGFRBKDRFFAR1 | |
| SCHEMBL29857652 | 0.82 | PDGFRB (0.43) | GSK3AGSK3BPDGFRBKDRFFAR1 | |
| SCHEMBL12327199 | 0.82 | ALDH1A1 (0.42) | GSK3AGSK3BPDGFRBKDRFFAR1 | |
| SCHEMBL30713566 | 0.82 | LPL (0.38) | GSK3AGSK3BPDGFRBKDRFFAR1 | |
| SCHEMBL3451096 | 0.79 | ALPL (0.43) | GSK3AGSK3BPDGFRBKDRFFAR1 | |
| SCHEMBL19212379 | 0.79 | GSK3A (0.33) | GSK3AGSK3BPDGFRBKDRFFAR1 | |
| SCHEMBL30905953 | 0.79 | ALPL (0.43) | GSK3AGSK3BPDGFRBKDRFFAR1 | |
| SCHEMBL22685874 | 0.78 | GSK3A (0.39) | GSK3AGSK3BPDGFRBKDRFFAR1 | |
| SCHEMBL18895034 | 0.78 | LPL (0.42) | GSK3AGSK3BPDGFRBKDRFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146512-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |